|
SG10202105964RA
(en)
*
|
2015-06-25 |
2021-07-29 |
Univ Health Network |
Hpk1 inhibitors and methods of using same
|
|
WO2018049191A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
|
US20180072741A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
|
US20180072718A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
MA46191A
(fr)
|
2016-09-09 |
2021-04-21 |
Incyte Corp |
Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
|
|
US20180228786A1
(en)
*
|
2017-02-15 |
2018-08-16 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
EP3596075B1
(en)
*
|
2017-03-15 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Azaindoles as inhibitors of hpk1
|
|
AU2018244935A1
(en)
*
|
2017-03-30 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Naphthyridines as inhibitors of HPK1
|
|
JP7129420B6
(ja)
*
|
2017-03-30 |
2024-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｐｋ１阻害剤としてのイソキノリン
|
|
EP3638671A1
(en)
|
2017-06-13 |
2020-04-22 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
CA3079060A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
|
|
EP3638669A1
(en)
|
2017-06-13 |
2020-04-22 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
WO2019016071A1
(en)
|
2017-07-18 |
2019-01-24 |
Bayer Pharma Aktiengesellschaft |
SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES
|
|
WO2019051199A1
(en)
*
|
2017-09-08 |
2019-03-14 |
Incyte Corporation |
6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
|
|
CN109721620B
(zh)
*
|
2017-10-27 |
2022-05-13 |
药捷安康(南京)科技股份有限公司 |
Hpk1抑制剂及其用途
|
|
EP3707138B1
(en)
*
|
2017-11-06 |
2022-07-13 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
SMT202200294T1
(it)
|
2018-02-20 |
2022-11-18 |
Incyte Corp |
Derivati di n-(fenil)-2-(fenil)pirimidina-4-carbossammide e composti correlati come inibitori di hpk1 per trattare il cancro
|
|
WO2019164847A1
(en)
|
2018-02-20 |
2019-08-29 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US11299473B2
(en)
|
2018-04-13 |
2022-04-12 |
Incyte Corporation |
Benzimidazole and indole compounds and uses thereof
|
|
JP7386842B2
(ja)
*
|
2018-07-24 |
2023-11-27 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ナフチリジン化合物およびその使用
|
|
WO2020023560A1
(en)
|
2018-07-24 |
2020-01-30 |
F. Hoffmann-La Roche Ag |
Isoquinoline compounds and uses thereof
|
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
|
EP3856348B1
(en)
|
2018-09-25 |
2024-01-03 |
Incyte Corporation |
Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
|
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
US11612606B2
(en)
|
2018-10-03 |
2023-03-28 |
Genentech, Inc. |
8-aminoisoquinoline compounds and uses thereof
|
|
WO2020072695A1
(en)
*
|
2018-10-03 |
2020-04-09 |
Genentech, Inc. |
8-aminoisoquinoline compounds and uses thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
PL3873903T3
(pl)
|
2018-10-31 |
2024-05-20 |
Gilead Sciences, Inc. |
Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1
|
|
US11071730B2
(en)
*
|
2018-10-31 |
2021-07-27 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
|
EP3894406A1
(en)
|
2018-12-11 |
2021-10-20 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
CN113874015B
(zh)
|
2018-12-21 |
2024-05-24 |
细胞基因公司 |
Ripk2的噻吩并吡啶抑制剂
|
|
CA3123699A1
(en)
*
|
2018-12-26 |
2020-07-02 |
Janssen Pharmaceutica Nv |
Thienopyridinone compounds
|
|
CA3129768A1
(en)
|
2019-03-26 |
2020-10-01 |
Laurence Anne Mevellec |
Hpk1 inhibitors
|
|
EP3947373B1
(en)
|
2019-03-26 |
2025-05-14 |
Janssen Pharmaceutica NV |
Bicyclic hpk1 inhibitors
|
|
WO2020235902A1
(ko)
*
|
2019-05-17 |
2020-11-26 |
주식회사 보로노이 |
헤테로고리 융합 피리미딘 유도체 및 이의 용도
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
US20210009718A1
(en)
|
2019-06-25 |
2021-01-14 |
Gilead Sciences, Inc. |
FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
|
|
TWI848141B
(zh)
|
2019-07-04 |
2024-07-11 |
英屬開曼群島商百濟神州有限公司 |
及其用途
|
|
CN112239473B
(zh)
|
2019-07-17 |
2023-12-08 |
百济神州(北京)生物科技有限公司 |
作为hpk1抑制剂的三环化合物的制备方法
|
|
KR20220059480A
(ko)
|
2019-08-06 |
2022-05-10 |
인사이트 코포레이션 |
고체 형태의 hpk1 억제제
|
|
KR20220105631A
(ko)
*
|
2019-09-13 |
2022-07-27 |
님버스 새턴 인코포레이티드 |
Hpk1 길항제 및 이의 용도
|
|
CN112552293A
(zh)
*
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
|
PH12022550835A1
(en)
|
2019-10-18 |
2023-07-03 |
Forty Seven Inc |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
CN114599392A
(zh)
|
2019-10-31 |
2022-06-07 |
四十七公司 |
基于抗cd47和抗cd20的血癌治疗
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
MX2022007930A
(es)
|
2019-12-24 |
2022-08-08 |
Carna Biosciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
BR112022011115A2
(pt)
*
|
2020-01-09 |
2022-08-23 |
Sumitomo Chemical Co |
Composto heterocíclico e composição de controle de artrópode nocivo, incluindo o mesmo
|
|
MX2022009947A
(es)
|
2020-02-14 |
2022-11-07 |
Jounce Therapeutics Inc |
Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
|
|
KR20230018365A
(ko)
*
|
2020-04-13 |
2023-02-07 |
유니버시티 헬스 네트워크 |
사이토카인 방출 증후군의 치료 방법
|
|
KR20230006891A
(ko)
|
2020-05-01 |
2023-01-11 |
길리애드 사이언시즈, 인코포레이티드 |
Cd73를 억제하는 2,4-다이옥소피리미딘 화합물
|
|
EP4149946A4
(en)
*
|
2020-05-11 |
2024-06-19 |
University Health Network |
SALT AND CRYSTALLINE FORMS OF 4-AMINO-5-(6-(4-METHYLPIPERAZIN-1-YL)-1H-BENZO[D!IMIDAZOL-2-YL)THIENO[2,3-B!PYRIDIN-6(7H)-ONE
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
CN113845531B
(zh)
*
|
2020-06-28 |
2025-06-27 |
四川科伦博泰生物医药股份有限公司 |
吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
|
|
KR20230104143A
(ko)
*
|
2020-09-28 |
2023-07-07 |
주식회사 퍼스트바이오테라퓨틱스 |
조혈 전구 키나아제 1(hpk1) 억제제로서의 인다졸 및 이의 사용 방법
|
|
TW202220975A
(zh)
|
2020-09-30 |
2022-06-01 |
英屬開曼群島商百濟神州有限公司 |
作為ｈｐｋ１抑制劑之３－［（１ｈ－吡唑－４－基）氧基］吡－２－胺化合物及其用途
|
|
WO2022098807A1
(en)
*
|
2020-11-09 |
2022-05-12 |
Merck Sharp & Dohme Corp. |
7-azole substituted 2-aminoquinazoline inhibitors of hpk1
|
|
JP2023550380A
(ja)
*
|
2020-11-24 |
2023-12-01 |
チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド |
重水素修飾チエノピリドン化合物
|
|
CN114805330A
(zh)
*
|
2021-01-22 |
2022-07-29 |
苏州信诺维医药科技股份有限公司 |
Hpk1抑制剂、其制备方法、药物组合物及其应用
|
|
US20240174683A1
(en)
|
2021-02-05 |
2024-05-30 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
CN114907377A
(zh)
*
|
2021-02-10 |
2022-08-16 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
JP2024506909A
(ja)
|
2021-02-12 |
2024-02-15 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
JP2024509192A
(ja)
|
2021-03-05 |
2024-02-29 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
CN116888127B
(zh)
*
|
2021-03-10 |
2025-09-02 |
轩竹生物科技股份有限公司 |
三并环类hpk1抑制剂及其用途
|
|
WO2022199676A1
(zh)
*
|
2021-03-26 |
2022-09-29 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
JP2024513011A
(ja)
|
2021-03-29 |
2024-03-21 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
WO2022226667A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ontario Institute For Cancer Research (Oicr) |
Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
|
|
US20240425479A1
(en)
*
|
2021-04-30 |
2024-12-26 |
Ontario Institute For Cancer Research (Oicr) |
Halo-substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
|
|
EP4330252A4
(en)
*
|
2021-04-30 |
2025-04-02 |
Ontario Institute for Cancer Research (OICR) |
Substituted aminoaza-heteroaryl compounds as inhibitors of hematopoietic precursor kinase 1 (HPC1)
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
WO2022253252A1
(en)
*
|
2021-06-03 |
2022-12-08 |
Silexon Biotech Co., Ltd. |
Heterocyclic compounds useful as hpk1 inhibitors
|
|
CN115433161A
(zh)
*
|
2021-06-04 |
2022-12-06 |
轶诺(浙江)药业有限公司 |
新型hpk1抑制剂及其制备方法和应用
|
|
US11976072B2
(en)
|
2021-06-23 |
2024-05-07 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
EP4359411A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
TW202321239A
(zh)
|
2021-07-20 |
2023-06-01 |
瑞典商阿斯特捷利康公司 |
作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺
|
|
US20250011331A1
(en)
*
|
2021-08-03 |
2025-01-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
WO2023023942A1
(en)
*
|
2021-08-24 |
2023-03-02 |
Biofront Ltd (Cayman) |
Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same
|
|
WO2023057882A1
(en)
*
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|
|
JP2024539633A
(ja)
*
|
2021-10-15 |
2024-10-29 |
ロモンド セラピューティクス，インコーポレイテッド |
置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用
|
|
JP2024539252A
(ja)
|
2021-10-28 |
2024-10-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ピリジジン－３（２ｈ）－オン誘導体
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
WO2023109902A1
(zh)
*
|
2021-12-17 |
2023-06-22 |
海思科医药集团股份有限公司 |
一种并环杂环衍生物及其在医药上的应用
|
|
EP4452415A1
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN118695862A
(zh)
*
|
2021-12-22 |
2024-09-24 |
大学健康网络 |
急性髓系白血病或淋巴瘤的治疗
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
WO2023138612A1
(en)
*
|
2022-01-19 |
2023-07-27 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as hpk1 inhibitors
|
|
CN118525026A
(zh)
*
|
2022-01-27 |
2024-08-20 |
西藏海思科制药有限公司 |
一种抑制或降解hpk1激酶的化合物及其在医药中的用途
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023151559A1
(zh)
*
|
2022-02-08 |
2023-08-17 |
和径医药科技（上海）有限公司 |
杂环化合物、包含其的药物组合物及其抗肿瘤应用
|
|
HUE069263T2
(hu)
|
2022-03-17 |
2025-02-28 |
Gilead Sciences Inc |
Ikarosz cink-ujj család degradálói és azok alkalmazása
|
|
JP2025509662A
(ja)
|
2022-03-24 |
2025-04-11 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｔｒｏｐ－２発現がんを治療するための併用療法
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
PE20250758A1
(es)
|
2022-07-01 |
2025-03-13 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
CN117624187B
(zh)
*
|
2022-11-17 |
2025-11-04 |
杭州阿诺生物医药科技有限公司 |
一种高效的hpk1降解剂化合物及其制备方法和应用
|
|
KR102855849B1
(ko)
|
2022-11-25 |
2025-09-08 |
충남대학교산학협력단 |
이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법
|
|
KR20250122479A
(ko)
|
2022-12-22 |
2025-08-13 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
WO2024206869A2
(en)
*
|
2023-03-30 |
2024-10-03 |
Board Of Regents, The University Of Texas System |
Combination of hpk1 inhibitor and axl inhibitor in cancer therapy
|
|
US20240383922A1
(en)
|
2023-04-11 |
2024-11-21 |
Gilead Sciences, Inc. |
KRAS Modulating Compounds
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
KR20250053739A
(ko)
*
|
2023-10-13 |
2025-04-22 |
주식회사유한양행 |
7,7-다이메틸푸로[3,4-b]피리딘-5(7H)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
|
|
WO2025096647A1
(en)
*
|
2023-10-30 |
2025-05-08 |
Nimbus Saturn, Inc. |
Methods of treating tumors
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|